France's Median Technologies H1 order backlog rises on demand from biopharmaceutical clients

Median Technologies SA

22/07/2026 17:19

    

    Overview
  
France AI medical imaging firm's H1 iCRO revenue rose 4.4% yr/yr to €11.8 mln
As of June 30, order backlog reached record €82.4 mln, up 15.6% yr/yr
Company completed €50 mln capital increase, boosting cash to €60.8 mln as of June 30

    

    Outlook
  
Company expects continued growth of iCRO business, supported by record backlog and commercial momentum
Median focused on executing U.S. commercial launch of eyonis LCS and expanding European market access
Company plans to advance development of eyonis portfolio for new indications beyond lung cancer screening

    

    Result Drivers
  
iCRO MOMENTUM - Co said H1 revenue growth and record backlog were driven by sustained demand from biopharmaceutical clients and continued momentum in its imaging services business
REGULATORY MILESTONES - FDA clearance and CE marking for eyonis LCS enabled commercial rollout in the U.S. and Europe, expanding addressable market

    
Company press release: ID:nBw4v9lXka

    

    Key Details
  

            Metric
          

            Beat/Miss
          

            Actual
          

            Consensus Estimate
          
H1 Revenue
 
EUR 11.80 mln
 
H1 Order Backlog
 
EUR 82.40 mln
 

    

    Analyst Coverage
  
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Median Technologies SA is €11.90, about 191% above its July 21 closing price of €4.09

    

    Reuters Recommended Reads
  
July 21 - France's Sidetrade H1 revenue rises 19% on AI product growth
July 21 - Celldex to stop skin disease study after trial setback
July 21 - Switzerland's Novartis beats Q2 sales estimates on strong sales across priority brands

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)